Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLZ-3001
- Development stage
- Preclinical
- Lead developer
- Cellatoz Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CLZ-3001 is an autologous natural killer cell therapy developed by Cellatoz Therapeutics for cancer treatment. The product consists of homogenized NK cells engineered or manufactured to highly express CD16 on the cell surface, with the intended mechanism of enhancing **CD16-mediated antibody-dependent cellular cytotoxicity** against tumor cells and potentially acting synergistically with immuno-oncology agents. Publicly described development has focused on neoplasms including ovarian cancer, with broader interest in solid tumors and possible exploration in glioblastoma; the program has been described as suitable for repeat dosing and aimed at restoring immune balance rather than simply transiently activating effector cells.
- Other names
- 16ENKsCD16-highly expressing natural killer cellsCD-16-highly expressing natural killer cellsCD 16-highly expressing natural killer cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on CLZ-3001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLZ-3001.